The metabolic syndrome, an epidemic among HIV-infected patients on HAART

Biomedicine and Pharmacotherapy

Volumn 63, Issue 5, 2009, Pages 337-342

  Jevtovic Dj ^a   Dragovic G ^a   Salemovic D ^a   Ranin, J ^a   Djurkovic Djakovic O ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

HAART; HIV; Metabolic syndrome (MS)

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; EPIDEMIC; FEMALE; GLUCOSE INTOLERANCE; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SERBIA; SEX DIFFERENCE; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOSE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPERLIPIDEMIAS; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; METABOLIC DISEASES; MIDDLE AGED; PREVALENCE; RISK FACTORS; SYNDROME; YOUNG ADULT;

EID: 68749122041     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.09.011     Document Type: Article

References (28)

1. Jacobson M.A., and French M.A.H. Altered natural history of AIDS-related opportunistic infections in the era of potent combination anti-retroviral therapy. AIDS 12 Suppl. A (1998) S157-S163
2. Gea-Banacloche J.C., and Lane C.H. Immune reconstitution in HIV infection. AIDS 13 Suppl. A (1999) S25-S38
3. Carr A., Miller J., Law M., and Cooper D.A. A syndrome of lipodystrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 19 (2000) 621-623
4. Lichtenstein K.A., Ward D.J., Moorman A.C., Delaney K.M., Young B., Palella Jr. F.J., et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15 (2001) 1389-1398
5. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 17 Suppl. 1 (2003) S141-S148
6. Miller J., Carr A., Emery S., Law M., Mallal S., Baker D., et al. HIV lipodystrophy. Prevalence, severity and correlates of risk in Australia. HIV Med 4 (2003) 293-301
7. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 41 RR-17 (1992) 1-19
8. Executive Summary of the Third Report of the National Cholesterol Education Program [NCEP] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
9. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershartz H., and Kannel W.B. Prediction of coronary heart disease using risk factors categories. Circulation 97 (1998) 1837-1847
10. Pakker N.G., Kroon E.D., Roos M.T., Otto S.A., Hall D., Wit F.V., et al. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. AIDS 13 (1999) 203-212
11. Jevtović D.J., Salemović D., Ranin J., Pešić I., Žerjav S., and Djurković-Djaković O. The dissociation between virological and immunological responses to HAART. Biomed Pharmacother 59 (2005) 446-451
12. Durant J., Clebenbergh P., Halfon P., Delguidice P., Porsin S., Simonet P., et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADEPT randomised controlled trial. Lancet 353 (1999) 2195-2199
13. Carr A., Miller J., Law M., and Cooper D.A. A syndrome of lipodystrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor related lipodystrophy syndrome. AIDS 14 (2000) F25-F32
14. Thiébaut R., Daucourt V., Mercié P., Ekouévi D.K., Malvy D., Morlat P., et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis 31 (2000) 1482-1487
15. Martinez E., Mocroft A., Garcia-Viejo A., Pérez-Cuevas J.B., Blanco J.L., Mallolas J., et al. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357 (2001) 592-598
16. Bogner J.R., Vielhauer V., Beckmann R.A., Michl G., Wille L., Salzberger B., et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 27 (2001) 237-244
17. Baufassa F., Dulioust A., Lascaux A., Meyer L., Boué F., Delfraissy J., et al. Lipodystrophy in 685 HIV-1 treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin Trials 2 (2001) 339-345
18. Miller JE, Emery S, French M, Baker D, Cooper D. The Australian prevalence survey of lipodystrophy syndrome. In: Program and abstracts of the seventh conference of retroviruses and opportunistic infections, San Francisco; January 2008 [Abst. 201].
19. Rodriguez-Guardado A., Maradona J.A., Asensi V., Carton J.A., and Casado L. Hepatitis C virus in patients with HIV infection and lipodystrophy. J Acquir Immune Defic Syndr 32 (2003) 348-349
20. Bedimo R., Ghurani R., Nsuami M., Turner D., Kvanli M.-B., Brown G., et al. Lipid abnormalities in HIV/hepatitis C virus-coinfected patients. HIV Med 7 (2006) 530-536
21. Anastos K., Lu D., Shi Q., Tien P.C., Kaplan R.C., Hessol N.A., et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr 45 (2007) 34-42
22. Brikman K., Smeitnik J.A., Romijn J.A., and Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354 (1999) 1112-1125
23. Gaou I., Malliti M., Guimont M.-C., Lettéron P., Demeilliers C., Peytavin G., et al. Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice. J Pharmacol Exp Ther 297 (2001) 516-523
24. Fontas E., Leith F.V., Sabin A., Friis-Moller N., Rickenbach M., d'Arminio Monforte A., et al. Lipid profiles in HIV-1 infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?. J Infect Dis 189 (2004) 1056-1074
25. Riddler S.A., Li X., Chu H., Kingsley L.A., Dobs A., Evans R., et al. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med 8 (2007) 280-287
26. Shlay J.C., Bartsch G., Peng G., Wang J., Grunfeld C., Gibert C.L., et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, non-nucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr 54 (2007) 506-517
27. Sabin C.A. Cardiovascular risk and choice of HIV drug regimen. Future HIV Ther 2 (2008) 83-92
28. The Data Collection on Adverse Events of Anti-HIV Drugs [DAD] Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 (2003) 1993-2003 [erratum N Engl J Med 2004; 350: 955]